[1]
|
Skorochod, R., Nesher, R., Nesher, G. and Gronovich, Y. (2021) Ophthalmic Adverse Events Following Facial Injections of Botulinum Toxin A: A Systemic Literature Review. Journal of Cosmetic Dermatology, 20, 2409-2413.
https://doi.org/10.1111/jocd.14279
|
[2]
|
Langenberg, J., Noort, D., Snyder, D. and Foster, K. (2018) AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients. Toxins (Basel), 10, 535. https://doi.org/10.3390/toxins10120535
|
[3]
|
Bellows, S. and Jankovic, J. (2019) Immunogenicity Associated with Botulinum Toxin Treatment. Toxins (Basel), 11, 491. https://doi.org/10.3390/toxins11090491
|
[4]
|
Gutierrez, S.A.S., Yu, J.R.T., Yalung, P.M. and Jamora, R.D.G. (2021) Real-World Experience with Botulinum Toxin A for the Treatment of Hemifacial Spasm: A Study of 1138 Injections. Clinical Neurology and Neurosurgery, 205, Article ID: 106632. https://doi.org/10.1016/j.clineuro.2021.106632
|
[5]
|
Mitsikostas, D.D., Dekundy, A., Hanschmann, A., Althaus, M., Scheschonka, A., Pagan, F. and Jankovic, J. (2021) Duration and Onset of Effect of IncobotulinumtoxinA for the Treatment of Blepharospasm in Botulinum Toxin-Naïve Subjects. Current Medical Research and Opinion, 37, 1761-1768. https://doi.org/10.1080/03007995.2021.1965975
|
[6]
|
Argyriou, A.A., Mitsikostas, D.D., Mantovani, E., Vikelis, M. and Tamburin, S. (2021) Beyond Chronic Migraine: A Systematic Review and Expert Opinion on the Off-Label Use of Botulinum Neurotoxin Type-A in Other Primary Headache Disorders. Expert Review of Neurotherapeutics, 21, 923-944.
https://doi.org/10.1080/14737175.2021.1958677
|
[7]
|
Marsili, L., Bologna, M., Jankovic, J. and Colosimo, C. (2021) Long-Term Efficacy and Safety of Botulinum Toxin Treatment for Cervical Dystonia: A Critical Reappraisal. Expert Opinion on Drug Safety, 20, 695-705.
https://doi.org/10.1080/14740338.2021.1915282
|
[8]
|
Dressler, D., Pan, L., Su, J., Teng, F. and Jin, L. (2021) Lantox—The Chinese Botulinum Toxin Drug-Complete English Bibliography and Comprehensive Formalised Literature Review. Toxins (Basel), 13, 370.
https://doi.org/10.3390/toxins13060370
|
[9]
|
Dressler, D. and Benecke, R. (2007) Pharmacology of Therapeutic Botulinum Toxin Preparations. Disability and Rehabilitation, 29, 1761-1768. https://doi.org/10.1080/09638280701568296
|
[10]
|
Abrams, S.B. and Hallett, M. (2013) Clinical Utility of Different Botulinum Neurotoxin Preparations. Toxicon, 67, 81-86. https://doi.org/10.1016/j.toxicon.2012.11.024
|
[11]
|
Satriyasa, B.K. (2019) Botulinum Toxin (Botox) A for Reducing the Appearance of Facial Wrinkles: A Literature Review of Clinical Use and Pharmacological Aspect. Clinical, Cosmetic and Investigational Dermatology, 12, 223-228.
https://doi.org/10.2147/CCID.S202919
|
[12]
|
Carr, W.W., Jain, N. and Sublett, J.W. (2021) Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications. Advances in Therapy, 38, 5046-5064. https://doi.org/10.1007/s12325-021-01882-9
|
[13]
|
Jankovic, J. (2017) Botulinum Toxin: State of the Art. Movement Disorders, 32, 1131-1138.
https://doi.org/10.1002/mds.27072
|
[14]
|
Rouientan, A., Alizadeh Otaghvar, H., Mahmoudvand, H. and Tizmaghz, A. (2019) Rare Complication of Botox Injection: A Case Report. World Journal of Plastic Surgery, 8, 116-119. https://doi.org/10.29252/wjps.8.1.116
|
[15]
|
Dressler, D. and Bigalke, H. (2017) Immunological Aspects of Botulinum Toxin Therapy. Expert Review of Neurotherapeutics, 17, 487-494. https://doi.org/10.1080/14737175.2017.1262258
|
[16]
|
Dressler, D. and Saberi, F.A. (2017) Safety of Botulinum Toxin Short Interval Therapy Using IncobotulinumtoxinA. Journal of Neural Transmission (Vienna), 124, 437-440. https://doi.org/10.1007/s00702-016-1628-0
|
[17]
|
Ray, J.C., Hutton, E.J. and Matharu, M. (2021) OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy. Journal of Clinical Medicine, 10, 2898. https://doi.org/10.3390/jcm10132898
|
[18]
|
Klein, A.W. (2002) Complications and Adverse Reactions with the Use of Botulinum Toxin. Disease-A-Month, 48, 336-356. https://doi.org/10.1053/mda.2001.25964
|
[19]
|
Nestor, M., Ablon, G. and Pickett, A. (2017) Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration. Aesthetic Surgery Journal, 37, S20-S31. https://doi.org/10.1093/asj/sjw282
|
[20]
|
Herrero-Infante, Y., Rodríguez-Sanz, A., Máñez-Miró, J. and Vivancos-Matellano, F. (2021) Hemifacial Spasm through the Last Three Decades: From Etiology to Efficacy and Safety of Long-Term Botulinum Toxin Treatment. Clinical Neurology and Neurosurgery, 203, Article ID: 106555. https://doi.org/10.1016/j.clineuro.2021.106555
|
[21]
|
Xu, L., Xu, W., Wang, J., Chong, Y., Liang, W. and Jiang, C. (2020) Persistent Abnormal Muscle Response after Microvascular Decompression for Hemifacial Spasm. Scientific Reports, 10, Article No. 18484.
https://doi.org/10.1038/s41598-020-75742-x
|
[22]
|
Nielsen, V.K. (1985) Electrophysiology of the Facial Nerve in Hemifacial Spasm: Ectopic/Ephaptic Excitation. Muscle Nerve, 8, 545-555. https://doi.org/10.1002/mus.880080702
|
[23]
|
Wang, A. and Jankovic, J. (1998) Hemifacial Spasm: Clinical Findings and Treatment. Muscle Nerve, 21, 1740-1747.
https://doi.org/10.1002/(SICI)1097-4598(199812)21:12<1740::AID-MUS17>3.0.CO;2-V
|
[24]
|
肉毒毒素治疗应用专家组, 中华医学会神经病学分会帕金森病及运动障碍学组. 中国肉毒毒素治疗应用专家共识[J]. 中华神经科杂志, 2018, 51(10): 779-786.
|
[25]
|
Liu, J., Li, F., Wu, G., Liu, B., Zhou, J., Fan, C., Jiao, F., Wang, D., Wu, G., Song, H. and Liu, R. (2021) Long-Term Retrospective Analysis of Re-do Microvascular Decompression in Patients with Hemifacial Spasm. Frontiers in Neurology, 12, Article ID: 687945. https://doi.org/10.3389/fneur.2021.687945
|
[26]
|
Wu, F., Wei, P., Wang, G., Wu, C., Hu, Y. and Hu, J. (2021) Roles of Preoperative Anxiety and Depression in the Outcomes of Microvascular Decompression in Hemifacial Spasm for Adolescent Patients. Medicine (Baltimore), 100, e26831. https://doi.org/10.1097/MD.0000000000026831
|
[27]
|
Batisti, J.P., Kleinfelder, A.D., Galli, N.B., Moro, A., Munhoz, R.P. and Teive, H.A. (2017) Treatment of Hemifacial Spasm with Botulinum Toxin Type A: Effective, Long Lasting and Well Tolerated. Arquivos de Neuro-Psiquiatria, 75, 87-91. https://doi.org/10.1590/0004-282x20160191
|
[28]
|
Kenney, C. and Jankovic, J. (2008) Botulinum Toxin in the Treatment of Blepharospasm and Hemifacial Spasm. Journal of Neural Transmission, 115, 585-591. https://doi.org/10.1007/s00702-007-0768-7
|
[29]
|
Dover, J.S., Monheit, G., Greener, M. and Pickett, A. (2018) Botulinum Toxin in Aesthetic Medicine: Myths and Realities. Dermatologic Surgery, 44, 249-260. https://doi.org/10.1097/DSS.0000000000001277
|
[30]
|
Sorgun, M.H., Yilmaz, R., Akin, Y.A., Mercan, F.N. and Akbostanci, M.C. (2015) Botulinum Toxin Injections for the Treatment of Hemifacial Spasm over 16 Years. Journal of Clinical Neuroscience, 22, 1319-1325.
https://doi.org/10.1016/j.jocn.2015.02.032
|
[31]
|
Jankovic, J., Kenney, C., Grafe, S., Goertelmeyer, R. and Comes, G. (2009) Relationship between Various Clinical Outcome Assessments in Patients with Blepharospasm. Movement Disorders, 24, 407-413.
https://doi.org/10.1002/mds.22368
|
[32]
|
Roggenkämper, P., Jost, W.H., Bihari, K., Comes, G. and Grafe, S. (2006) Efficacy and Safety of a New Botulinum Toxin Type A Free of Complexing Proteins in the Treatment of Blepharospasm. Journal of Neural Transmission (Vienna), 113, 303-312. https://doi.org/10.1007/s00702-005-0323-3
|
[33]
|
中华医学会神经病学分会, 中华医学会神经病学分会帕金森病及运动障碍学组. 肌张力障碍诊断中国专家共识[J]. 中华神经科杂志, 2020, 53(1): 8-12.
|
[34]
|
Simpson, D.M., Hallett, M., Ashman, E.J., Comella, C.L., Green, M.W., Gronseth, G.S., Armstrong, M.J., Gloss, D., Potrebic, S., Jankovic, J., Karp, B.P., Naumann, M., So, Y.T. and Yablon, S.A. (2016) Practice Guideline Update Summary: Botulinum Neurotoxin for the Treatment of Blepharospasm, Cervical Dystonia, Adult Spasticity, and Headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 86, 1818-1826. https://doi.org/10.1212/WNL.0000000000002560
|
[35]
|
Pandey, S. and Sharma, S. (2017) Meige’s Syndrome: History, Epidemiology, Clinical Features, Pathogenesis and Treatment. Journal of the Neurological Sciences, 372, 162-170. https://doi.org/10.1016/j.jns.2016.11.053
|
[36]
|
Gamain, J., Herr, T., Fleischmann, R., Stenner, A., Vollmer, M., Willert, C., Veit, B., Lehnert, B., Mueller, J.U., Steigerwald, F., Tost, F. and Kronenbuerger, M. (2021) Smell and Taste in Idiopathic Blepharospasm. Journal of Neural Transmission (Vienna), 128, 1215-1224. https://doi.org/10.1007/s00702-021-02366-4
|
[37]
|
Albanese, A., Asmus, F., Bhatia, K.P., Elia, A.E., Elibol, B., Filippini, G., Gasser, T., Krauss, J.K., Nardocci, N., Newton, A. and Valls-Solé, J. (2011) EFNS Guidelines on Diagnosis and Treatment of Primary Dystonias. European Journal of Neurology, 18, 5-18. https://doi.org/10.1111/j.1468-1331.2010.03042.x
|
[38]
|
Jankovic, J., Comella, C., Hanschmann, A. and Grafe, S. (2011) Efficacy and Safety of IncobotulinumtoxinA (NT 201, Xeomin) in the Treatment of Blepharospasm—A Randomized Trial. Movement Disorders, 26, 1521-1528.
https://doi.org/10.1002/mds.23658
|
[39]
|
Ma, H., Qu, J., Ye, L., Shu, Y. and Qu, Q. (2021) Blepharospasm, Oromandibular Dystonia, and Meige Syndrome: Clinical and Genetic Update. Frontiers in Neurology, 12, Article ID: 630221.
https://doi.org/10.3389/fneur.2021.630221
|
[40]
|
Duarte, G.S., Rodrigues, F.B., Marques, R.E., Castelão, M., Ferreira, J., Sampaio, C., Moore, A.P. and Costa, J. (2020) Botulinum Toxin Type A Therapy for Blepharospasm. Cochrane Database of Systematic Reviews, 11, CD004900.
https://doi.org/10.1002/14651858.CD004900.pub3
|
[41]
|
Tang, M., Li, W., Ji, F., Li, X., Zhang, Y. and Liu, P. (2019) Impact of Botulinum Toxin Injections on Quality of Life and Self-Esteem in Patients with Blepharospasm. Psychology, Health & Medicine, 24, 513-518.
https://doi.org/10.1080/13548506.2018.1549740
|
[42]
|
Tyślerowicz, M., Kiedrzyńska, W., Adamkiewicz, B., Jost, W.H. and Sławek, J. (2020) Cervical Dystonia—Improving the Effectiveness of Botulinum Toxin Therapy. Neurologia i Neurochirurgia Polska, 54, 232-242.
https://doi.org/10.5603/PJNNS.a2020.0021
|
[43]
|
Castelão, M., Marques, R.E., Duarte, G.S., Rodrigues, F.B., Ferreira, J., Sampaio, C., Moore, A.P. and Costa, J. (2017) Botulinum Toxin Type A Therapy for Cervical Dystonia. Cochrane Database of Systematic Reviews, 12, CD003633.
https://doi.org/10.1002/14651858.CD003633.pub3
|
[44]
|
Jinnah, H.A., Comella, C.L., Perlmutter, J., Lungu, C. and Hallett, M. (2018) Longitudinal Studies of Botulinum Toxin in Cervical Dystonia: Why Do Patients Discontinue Therapy? Toxicon, 147, 89-95.
https://doi.org/10.1016/j.toxicon.2017.09.004
|
[45]
|
Leplow, B., Eggebrecht, A. and Pohl, J. (2017) Treatment Satisfaction with Botulinum Toxin: A Comparison between Blepharospasm and Cervical Dystonia. Patient Preference and Adherence, 11, 1555-1563.
https://doi.org/10.2147/PPA.S141060
|
[46]
|
Davidescu, E.I., Odajiu, I., Tulbă, D., Mitrea, I., Cucu, C. and Popescu, B.O. (2021) Psychological Traits and Behavioural Influences in Patients with Dystonia—An Observational Cohort Study in a Romanian Neurology Department. Life (Basel), 11, 612. https://doi.org/10.3390/life11070612
|